Please upgrade your browser.
The 2004 EU Clinical Trials Directive is discouraging new trials from taking place and thus harming patients. Will the USA, under the ACA, head in the same direction?
At a time when Penn State University is taking a beating in the media and in the public eye, it's easy to forget how much good is being done at the university.
The findings suggest similar effects among men and women, and for all types of alcohol beverages.
... NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma...
Football team raises more than $110,000 for Kidney Cancer Association
"Another Side of the Conversation" demonstrates the importance of maintaining effective communications with your medical team.
The Atlantic Cancer Research Institute's (ACRI) work in the improvement of kidney cancer treatment and in the better understanding of cancer cell functions has been given a boost thanks to two prestigious grants recently obtained.
Conflicting studies presented at the annual meeting of the American Society of Clinical Oncology suggest that â for now at least â itâs a toss-up.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel â undetected by normal cells â through the bloodstream until activated by specific cancer proteins.
You read about first at KidneyCancer.org: In metastatic renal-cell cancer, the level of cytokines and angiogenic factors (CAF) identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.
|Powered by NeonCRM|